查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲器官移植診斷市場：分析與預測，2023-2033
市場調查報告書
商品編碼
1413712

歐洲器官移植診斷市場：分析與預測，2023-2033

Europe Organ Transplant Diagnostics Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 62 Pages | 商品交期: 1-5個工作天內

價格

歐洲器官移植診斷市場規模預計將從 2023 年的 11.6 億美元增加到 2033 年的 33.5 億美元，預測期內複合年成長率為 11.15%。

導致器官衰竭的慢性疾病數量迅速增加、移植診斷的使用不斷增加、幹細胞療法的接受度不斷提高、白血病患者數量的增加推動了對移植診斷測試的需求、分子和基因組技術進步帶來的好處移植診斷領域；幾個關鍵因素正在推動市場的成長，包括有利的監管條件的存在，包括報銷設施。

主要市場統計數據
預測期 2023-2033
2023年評估 11.6億美元
2033年預測 33.5億美元
複合年成長率 11.15%

本報告調查了歐洲器官移植診斷市場，總結了市場概況、市場成長的各種影響因素分析、市場規模趨勢和預測、主要國家的詳細分析以及主要企業的分析。

市場分類

細分 1：按國家/地區

  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 瑞士
  • 其他

主要企業：

  • BAG Group GmbH
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Eurobio Scientific (Genome Diagnostics BV)
  • Omixon Inc.
  • QIAGEN NV

目錄

執行摘要

第1章 產品定義

第2章 市場範圍

第3章調查方法

第4章概述

  • 目前的市場狀況
    • 研究機構使用
    • 診斷用途
  • 市場足跡
  • COVID-19 對市場的影響

第5章 歐洲

  • 歐洲
    • 歐洲器官移植試驗數量：依移植類型分類
    • 市場規模/預測

第6章 公司簡介

  • 製造商
Product Code: BHP1803SS

“The Europe Organ Transplant Diagnostics Market Expected to Reach $3.35 Billion by 2033.”

Introduction to Europe Organ Transplant Diagnostics Market

In 2023, the Europe organ transplant diagnostics market was valued at $1.16 billion and is expected to reach $3.35 billion by 2033, with a CAGR of 11.15% during the forecast period 2023-2033. Several key factors are propelling growth in this sector, including a surge in the prevalence of chronic diseases resulting in organ failure, a heightened utilization of transplant diagnostics, a growing acceptance of stem cell therapy, an increase in leukemia cases driving demand for transplant diagnostic tests, the benefits derived from the advancement of molecular and genomic technologies in the field of transplant diagnostics, and the existence of favorable regulatory conditions, encompassing reimbursement schemes.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$1.16 Billion
2033 Forecast$3.35 Billion
CAGR11.15%

Market Introduction

The Europe organ transplant diagnostics market is experiencing significant growth driven by factors such as the increasing incidence of chronic diseases leading to organ failure. This rise in conditions like kidney, liver, and heart diseases fuels the demand for organ transplants and subsequently, transplant diagnostics. Adoption of transplant diagnostics is on the upswing due to advancements in medical technology and heightened awareness of the importance of pre-transplant compatibility testing. The growing acceptance of stem cell therapy also contributes to the demand for transplant diagnostics. Additionally, the prevalence of leukemia cases necessitates accurate diagnostic tests before bone marrow or stem cell transplantation. Advanced molecular and genomic technologies in transplant diagnostics enhance compatibility assessments. Europe's favorable regulatory environment, including reimbursement schemes, encourages investment in transplant diagnostics by healthcare providers and patients alike. These factors collectively drive growth in the Europe organ transplant diagnostics market, making it a dynamic sector for healthcare advancements.

Market Segmentation:

Segmentation 1: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Switzerland
  • Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities.

Competitive Strategy: The key players in the Europe organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the Europe organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

  • BAG Group GmbH
  • bioMerieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Eurobio Scientific (Genome Diagnostics B.V.)
  • Omixon Inc.
  • QIAGEN N.V.

Table of Contents

Executive Summary

1. Product Definition

  • 1.1. Inclusion and Exclusion Criteria

2. Market Scope

  • 2.1. Key Questions Answered in the Report:

3. Research Methodology

  • 3.1. Organ Transplant Diagnostics Market: Research Methodology
  • 3.2. Data Sources
    • 3.2.1. Primary Data Sources
    • 3.2.2. Secondary Data Sources
  • 3.3. Market Estimation Model
  • 3.4. Criteria for Company Profiling

4. Overview

  • 4.1. Current Market Scenario
    • 4.1.1. For Researchers
    • 4.1.2. For Diagnostics
  • 4.2. Market Footprint
  • 4.3. COVID-19 Impact on Market
    • 4.3.1. Impact on Operations
    • 4.3.2. COVID-19 Impact: Current Scenario of Market
    • 4.3.3. Pre- and Post-COVID-19 Impact Assessment
      • 4.3.3.1. Pre-COVID-19 Phase
      • 4.3.3.2. Post-COVID-19 Phase

5. Europe

  • 5.1. Europe
    • 5.1.1. Europe Organ Transplant Test Volume, by Transplant Type
    • 5.1.2. Market Sizing and Forecast
      • 5.1.2.1. Europe Organ Transplant Diagnostics Market (by Country)
        • 5.1.2.1.1. France
        • 5.1.2.1.2. Spain
        • 5.1.2.1.3. U.K.
        • 5.1.2.1.4. Italy
        • 5.1.2.1.5. Germany
        • 5.1.2.1.6. Switzerland
        • 5.1.2.1.7. Rest-of-Europe

6. Company Profiles

  • 6.1. Overview
  • 6.2. Manufacturers
    • 6.2.1. BAG Group GmbH
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
      • 6.2.1.3. Product Portfolio
      • 6.2.1.4. Analyst Perception
    • 6.2.2. bioMerieux S.A.
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Role of bioMerieux S.A. in the Organ Transplant Diagnostics Market
      • 6.2.2.3. Product Portfolio
      • 6.2.2.4. Financials
      • 6.2.2.5. Recent Developments
      • 6.2.2.6. Analyst Perception
    • 6.2.3. Eurobio Scientific (Genome Diagnostics B.V.)
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
      • 6.2.3.3. Product Portfolio
      • 6.2.3.4. Analyst Perception
    • 6.2.4. F. Hoffmann-La Roche Ltd.
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
      • 6.2.4.3. Product Portfolio
      • 6.2.4.4. Financials
      • 6.2.4.5. Recent Developments
      • 6.2.4.6. Analyst Perception
    • 6.2.5. Omixon Inc.
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Role of Omixon Inc. in the Organ Transplant Diagnostics Market
      • 6.2.5.3. Product Portfolio
      • 6.2.5.4. Analyst Perception
    • 6.2.6. QIAGEN N.V.
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
      • 6.2.6.3. Product Portfolio
      • 6.2.6.4. Financials
      • 6.2.6.5. Recent Developments
      • 6.2.6.6. Analyst Perception

List of Figures

  • Figure 1: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
  • Figure 2: Organ Transplant Diagnostics Market, Impact Analysis
  • Figure 3: Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
  • Figure 4: Organ Transplant Diagnostics Market: Research Methodology
  • Figure 5: Primary Research Methodology
  • Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 8: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
  • Figure 9: Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
  • Figure 10: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
  • Figure 11: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
  • Figure 12: France Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 13: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 14: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 15: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 16: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 17: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 18: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
  • Figure 19: Total Number of Companies Profiled
  • Figure 20: Organ Transplant Diagnostics Market Overview, Key Companies
  • Figure 21: BAG Group GmbH: Overall Product Portfolio
  • Figure 22: bioMerieux S.A.: Overall Product Portfolio
  • Figure 23: bioMerieux S.A.: Overall Financials, $Million, 2019-2021
  • Figure 24: bioMerieux S.A.: Net Revenue (by Region), $Million, 2019-2021
  • Figure 25: bioMerieux S.A.: R&D Expenditure, $Million, 2019-2021
  • Figure 26: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
  • Figure 27: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
  • Figure 28: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
  • Figure 29: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
  • Figure 30: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
  • Figure 31: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
  • Figure 32: Omixon Inc.: Overall Product Portfolio
  • Figure 33: QIAGEN N.V.: Product Portfolio
  • Figure 34: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
  • Figure 35: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
  • Figure 36: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
  • Figure 37: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Europe Organ Transplant Diagnostics Market, Impact Analysis
  • Table 3: Europe Organ Transplant Test Volume, by Transplant Type, 2021